The desferrithiocin (DFT) class of iron chelators: Potential as antineoplastic agents

Anti-Cancer Drug Design

Volumn 16, Issue 4-5, 2001, Pages 195-207

  Kicic, Anthony ^a   Chua, Anita C G ^a   Baker, Erica ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cancer; Desferrioxamine; Desferrithiocin; Fe chelators; Fetal and adult derived hepatoma cells

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; CGP 28500; CGP 52547; CGP 52548; CHELATING AGENT; DEFEROXAMINE; DEFERRIFERRITHIOCIN; DESAZANORDESFERRITHIOCIN; IRON; IRON CHELATOR; NORDESFERRITHIOCIN; PYRIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; FETUS; FIBROBLAST; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; IRON TRANSPORT; LIVER CELL; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; DEFEROXAMINE; DIHYDROPYRIDINES; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; HEPATOCYTES; HUMAN; IRON; IRON CHELATING AGENTS; IRON RADIOISOTOPES; LIVER NEOPLASMS, EXPERIMENTAL; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0035437385     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Aldouri M.A., Wonke B., Hoffbrand A.V., Flynn D.M., Laulicht M., Fenton L.A., Scheuer P.J., Kibbler C.C., Allwood C.A., Brown D., Thomas HC. (1987) Iron state and hepatic disease in patients with thalassaemia major; treated with long term subcutaneous desferrioxamine. Journal of Clinical Pathology, 40, 1353.
2. Baker E., Lloyd D., Morgan E.H., Yeoh G.C.T. (1988) Iron metabolism and the effects of iron chelators in rat hepatoma cells. Birth Defects: Original Article Series, 23, 89.
3. Baker E., Richardson D.R., Gross S., Ponka P. (1992a) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology, 15, 492.
4. Baker E., Vitolo M.L., Webb J. (1985) Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochemical Pharmacology, 34, 3011.
5. Baker E., Wong A., Peter H., Jacobs A. (1992b) Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. British Journal of Haematology, 81, 424.
6. Becker E., Richardson D.R. (1999) Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogues. Journal of Laboratory and Clinical Medicine, 134, 510.
7. Becton D.L., Bryles P. (1988) Desferrioxamine inhibition of human neuroblastoma viability and proliferation. Cancer Research, 48, 7189.
8. Bergeron R.J., Wiegand J., Dionis J.B., Egli-Karmakka M., Frei J., Huxley-Tencer A., Peter H.H. (1991) Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. Journal Medical Chemistry, 34, 2072.
9. Bergeron R.J., Streiff R.R., Creary E.A., Daniels R.D. Jr, King W., Luchetta G., Wiegand J., Moerker T., Peter H. (1993) A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood, 81, 2166.
10. Blatt J., Taylor S.R., Stitely S. (1988) Mechanisms of anti-neuroblastoma activity of desferrioxamine in vitro. Journal of Laboratory and Clinical Medicine, 112, 433.
11. 1 phase of the cell cycle. Cancer Research, 53, 3968.
12. Chitambar C.R., Massey E.J., Seligman P.A. (1983) Regulation of transferrin receptor expression on human leukaemic cells during proliferation and induction of differentiation. Journal of Clinical Investigation, 72, 1314.
13. Chou J.Y. (1983) Temperature-sensitive adult liver cell line dependent on glucocorticoid for differentiation. Molecular and Cellular Biology, 3, 1013.
14. Chou J.Y., Ito F. (1983) Temperature-sensitive fetal liver cells: A model for hepatocellular differentiation. Annals New York Academy Science, 417, 308.
15. Darnell G., Richardson D.R. (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. III. The effect of ligands on molecular targets involved in proliferation. Blood, 94, 781.
16. Enns C.A., Mulkins M.A., Sussman H., Root B. (1987) Modulation of the transferrin receptor during DMSO-induced differentiation in HL-60 cells. Experimental Cell Research, 174, 89.
17. Estrov Z., Tawa A., Zwang X.-H., Dube I.D., Sulh H., Cohen A., Gelfand E.W., Freedman M.H. (1987) In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood, 69, 757.
18. Hanks J.H., Wallace R.E. (1949) Relation of oxygenation and temperature in preservation of tissues by refrigeration. Proceedings of the Society for Experimental Biology and Medicine, 71, 196.
19. Hann F.G., McMurry T.J., Hugi A., Raymond K.N. (1990) Structural and spectreoscopic characterisation of diastereomeric Cr (III) and Co (III) complexes of desferrithiocin. Journal of the American Chemistry Society, 112, 1854.
20. Hemmaplardh D., Morgan E.H. (1977) The role of endocytosis in the transferrin uptake by reticulocytes and bone marrow cells. British Journal of Haematology, 36, 85.
21. Kaplinsky C., Estrov Z., Freedman M.H., Gelfand E.W., Cohen A. (1987) Effect of desferrioxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia, 1, 437.
22. Kemp K., Kanner L.J., Franscisco G., Thorson J.A., Naulmann P.W. (1990) Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator desferrioxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood, 76, 991.
23. Morgan E.H., Baker E. (1986) Iron uptake and metabolism by hepatocytes. Federal Proceedings, 45, 2810.
24. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: Application for proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55.
25. Nastruzzi P., Menegatti E., Gambari R. (1989) Differential effects of liposomes-entrapped desferrioxamine on proliferation and erythroid differentiation of murine erythroleukemic Friend cells. Biochimica et Biophysica Acta, 1013, 36.
26. Ponka P., Borova J., Neuwirt J., Fuchs O. (1979a) Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Letters, 97, 317.
27. Ponka P., Borova J., Neuwirt J., Fuchs O., Necas E. (1979b) A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochimica et Biophysica Acta, 586, 278.
28. Richardson D.R. (1997a) Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leukaemia and Lymphoma, 31, 47.
29. Richardson D.R. (1997b) Cytotoxic analogues of the iron (III) chelator pyridoxal isonicotinoyl hydrazone; effects of complexation with copper (II), gallium (III), and iron (III) on their antiproliferative activities. Antimicrobial Agents and Chemotherapy, 41, 2061.
30. Richardson D.R., Baker E. (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochimica et Biophysica Acta, 1053, 1.
31. Richardson D.R., Baker E. (1991) The uptake of inorganic iron complexes by human malignant melanoma cells. Biochimica et Biophysica Acta, 1093, 20.
32. Richardson D.R., Baker E. (1992) Two mechanisms of iron uptake from transferrin by melanoma cells. Journal of Biological Chemistry, 267, 13972.
33. Richardson D.R., Baker E. (1994) Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. Journal of Cellular Physiology, 161, 160.
34. Richardson D.R., Milnes K. (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89, 3025.
35. Richardson D.R., Ponka P. (1994) The iron metabolism of the human neuroblastoma cell: Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. Journal of Laboratory and Clinical Medicine, 124, 660.
36. Richardson D.R., Ponka P. (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochimica et Biophysica Acta, 1331, 1.
37. Richardson D.R., Ponka P., Baker E. (1994) The effects of the iron (III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Research, 54, 685.
38. Richardson D.R., Tran E.H., Ponka P. (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86, 4295.
39. Selig R.A., Madafiglio J., Haber M., Norris M.D., White L., Stewart B.W. (1993) Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines. Anticancer Research, 13, 721.
40. Taetle R., Rhyner K., Castagnola J., To D., Mendelsohn J. (1985) Role of transferrin, Fe, and transferrin receptors in myeloid leukaemia cell growth. Journal of Clinical Investigation, 75, 1061.
41. Timeus F, Valle P, Crescenzio N, Ruggieri L, Rosso P, Pagliardi GL, Cordero di Montezemolo L, Gabutti V, Ramenghi U. (1994) Effect of desferrioxamine and hydroxypyridinones on hemopoietic progenitors and neuroectodermal tumor cells. American Journal of Haematology, 47, 183.
42. Torti S.V., Torti EM., Whitman S.P., Brechbiel M.W., Park G., Planalp R.P. (1998) Tumor cell cytotoxicity of a novel iron chelator. Blood, 92, 1384.
43. Trepel J.B., Colamonici O., Kelly K., Schwab G., Watt R.A., Sausville E.A., Jaffe E.S., Neckers L.M. (1987) Transcriptional inactivation of c-myc and the transferrin receptor in dibutyrylcyclic AMP-treated HL-60 cells. Molecular and Cellular Biology, 7, 2644.
44. Trinder D., Zak O., Aisen P. (1996) Transferrin receptorindependent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology, 23, 1512.
45. Trinder D., Morgan E.H., Baker E. (1986) The mechanisms of Fe uptake by fetal rat hepatocytes in culture. Hepatology, 6, 852.
46. Yeoh G.C.T., Hilliard C., Fletcher S., Douglas A. (1990) Gene expression in clonally derived cell lines produced by in vitro transformation of rat fetal hepatocytes: Isolation of cell lines which retain liver specific markers. Cancer Research, 50, 7593.
47. Yeoh G.C.T., Porter I., Arcus M., Douglas A. (1989) Transformation of cultured fetal rat liver cells by MDAB and phenobarbital. Morphological, biochemical and immunocytochemical characterization of cell lines. Carcinogenesis, 10, 1015.